iShares Biotechnology ETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
iShares Biotechnology ETF IBB
Morningstar’s Analysis IBB
Will IBB outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Vertex Pharmaceuticals Inc | 7.83 | 732M | Healthcare |
Amgen Inc | 7.81 | 730M | Healthcare |
Gilead Sciences Inc | 7.13 | 667M | Healthcare |
Regeneron Pharmaceuticals Inc | 5.23 | 489M | Healthcare |
argenx SE ADR | 3.56 | 333M | Healthcare |
Alnylam Pharmaceuticals Inc | 2.99 | 280M | Healthcare |
Natera Inc | 2.91 | 272M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 2.74 | 256M | Healthcare |
Biogen Inc | 2.39 | 224M | Healthcare |
Illumina Inc | 2.24 | 210M | Healthcare |